Medlab Clinical Limited (ASX:MDC) dropped 4% during mid-day trading on Friday . The stock traded as low as A$0.48 ($0.34) and last traded at A$0.48 ($0.34), approximately 174,462 shares were traded during mid-day trading. The stock had previously closed at A$0.50 ($0.35).

The company has a debt-to-equity ratio of 6.48, a current ratio of 3.83 and a quick ratio of 3.06. The stock has a market cap of $100.24 million and a price-to-earnings ratio of -12.18. The stock has a 50 day moving average of A$0.45.

In other news, insider Michael Hall 850,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st.

About Medlab Clinical (ASX:MDC)

Medlab Clinical Limited, a medical research and development facility, engages in nutraceutical products and pharmaceutical research businesses in Australia. The company develops bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, musculoskeletal muscle loss associated with ageing, and non-opioid pain management.

Read More: What is the cash asset ratio?

Receive News & Ratings for Medlab Clinical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medlab Clinical and related companies with MarketBeat.com's FREE daily email newsletter.